| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vivo |
In big animals, firibastat (0.1–30 mg/kg; po) improves cardiovascular health by piercing the blood-brain barrier, entering the brain, and producing two EC33 active molecules. It also dilates blood vessels, suppresses brain APA activity, and generates brain angiotensin III.
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Normotensive and hypertensive DOCA-salt rats [1]
Doses: 0.1-30 mg/kg Route of Administration: Po Experimental Results:Caused a dose-dependent decrease in mean arterial blood pressure (MABP) for several hrs (hrs (hours)) [2]. . |
| References |
|
| Additional Infomation |
QGC001 has been used in trials studying the treatment of Essential Hypertension.
|
| Molecular Formula |
C8H20N2O6S4
|
|---|---|
| Molecular Weight |
368.49
|
| Exact Mass |
368.02
|
| Elemental Analysis |
C, 26.08; H, 5.47; N, 7.60; O, 26.05; S, 34.80
|
| CAS # |
648927-86-0
|
| Related CAS # |
648927-86-0 (free);648927-86-0 (3hydrate);1601301-47-6 (disodium);
|
| PubChem CID |
24851355
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.629
|
| LogP |
-2.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
20
|
| Complexity |
410
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
S(CC[C@H](CSSC[C@@H](CCS(=O)(=O)O)N)N)(=O)(=O)O
|
| InChi Key |
HJPXZXVKLGEMGP-YUMQZZPRSA-N
|
| InChi Code |
InChI=1S/C8H20N2O6S4/c9-7(1-3-19(11,12)13)5-17-18-6-8(10)2-4-20(14,15)16/h7-8H,1-6,9-10H2,(H,11,12,13)(H,14,15,16)/t7-,8-/m0/s1
|
| Chemical Name |
(3S)-3-amino-4-[[(2S)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid
|
| Synonyms |
RB-150 RB150 QGC-001 RB 150 QGC 001 QGC001
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~33.33 mg/mL (~90.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (271.36 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7138 mL | 13.5689 mL | 27.1378 mL | |
| 5 mM | 0.5428 mL | 2.7138 mL | 5.4276 mL | |
| 10 mM | 0.2714 mL | 1.3569 mL | 2.7138 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01900171 | COMPLETED | Drug: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)] Drug: Placebo |
Essential Hypertension | Quantum Genomics SA | 2012-02 | Phase 1 |
| NCT02322450 | COMPLETED | Drug: QGC001 Drug: Placebo |
Essential Hypertension | Quantum Genomics SA | 2015-01 | Phase 2 |
| NCT01900184 | COMPLETED | Drug: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)] Drug: Placebo |
Essential Hypertension | Quantum Genomics SA | 2012-12 | Phase 1 |
| NCT03714685 | COMPLETED | Drug: Firibastat | Healthy Males | Quantum Genomics SA | 2019-02-15 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
